Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief strategy officer said. Mitsubishi Tanabe Pharma is being sold to Bain Capital ...

(RTTNews) - Astellas Pharma Inc. (ALPMY, ALPMY) announced that the U.S. Food and Drug Administration approved expanded U.S. Prescribing information for IZERVAY (avacincaptad pegol intravitreal ...

Marci English, head of biopharma and ophthalmology development at Astellas Pharma, said the FDA's change of heart will "further [solidify] Izervay's status as a trusted choice for thousands of GA ...

Astellas is focusing on solid tumors and regeneration of the back of the eye. For gene therapy, the Japanese pharma remains hopeful that it can eventually build a presence in neuromuscular ...

Pfizer (PFE) and Astellas Pharma announced additional follow-up results from the Phase 3 EV-302 clinical trial evaluating the efficacy and safety of PADCEV, or enfortumab vedotin-ejfv, a Nectin-4 ...

On Monday, Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (OTC:ALPMF) (OTC:ALPMY) released additional follow-up results from the Phase 3 EV-302 trial (also known as KEYNOTE-A39) of Padcev ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Jefferies analyst Stephen Barker maintained a Hold rating on Astellas Pharma (ALPMF – Research Report) yesterday and set a price target of Yen1,700.00. The company’s shares closed last ...

Enfortumab vedotin plus pembrolizumab cut the risk of death by 49% vs. chemo, with a median OS of 33.8 months vs. 15.9 months. The combination therapy reduced disease progression or death risk by ...

Caela Shay left Verily to lead U.S. communications at ResMed. Astellas Pharma announced chief medical officer Tadaaki Taniguchi, MD, PhD moved to a newly created position of chief research and ...

(RTTNews) - Astellas Pharma Inc. (ALPMY) Wednesday announced the submission of a New Drug Application or NDA in Japan for Conditional Approval of Avacincaptad Pegol intravitreal solution or ACP ...

Astellas is to work with UK biotech Adaptimmune Therapeutics to develop allogeneic ‘off-the-shelf’ T-cell therapies for cancer. The Japanese pharma said its wholly-owned subsidiary Universal ...